Survo Dual Glucagon Receptor & GLP-1 Receptor Agonist (GCGR/GLP-1R)

TECHNICAL SPECIFICATIONS

Disclaimer : For Research Use Only (RUO). Not for human use.

Product Overview

Discovery and Scientific Background :

Survo (BI 456906) is an acylated synthetic peptide used as a research tool for GCGR and GLP-1R signalling assays. Relevant laboratory endpoints include receptor binding, cAMP signalling, and peptide stability.

The molecular design includes a glucagon-based peptide backbone and a C18 acyl modification associated with albumin binding. These features provide a basis for receptor activity and structure-activity studies.

For laboratory research use only. Not for use in humans or animals.

Molecular Architecture

Survo’s molecular architecture includes three key structural features:

• • Glucagon-based 29-amino-acid backbone ; Provides the scaffold for dual GCGR/GLP-1R engagement. Native glucagon is a potent GCGR agonist but has negligible GLP-1R activity; the Survo sequence introduces modifications at multiple positions to confer GLP-1R agonism alongside GCGR activity.

• • Ac4c at position 2 ; The non-coded amino acid 1-aminocyclobutane-1-carboxylic acid (Ac4c) replaces the native position 2 residue, enhancing receptor selectivity and resistance to proteolytic degradation ; a critical requirement for a long-acting research compound.

• • C18 fatty diacid at position 24 ; Conjugated via a hydrophilic glycine-serine linker, the C18 fatty diacid enables reversible albumin binding, supporting albumin-binding studies in defined assay systems.

LC-MS identity confirmation per batch COA must verify intact C18 acyl chain conjugation ; the free (de-acylated) peptide has fundamentally different pharmacology and would not serve as a valid research tool for albumin-dependent GCGR/GLP-1R dual agonism studies.

Survo (BI 456906; CID 168429725) full molecular structure C192H289N47O61 29-residue dual GCGR/GLP-1R agonist showing glucagon-based peptide backbone, non-coded Ac4c residue at position 2, and C18 fatty diacid conjugation at position 24 via glycine-serine hydrophilic linker

Research Mechanism -2026 Laboratory Applications

All applications below concern laboratory research assays. Not for use in humans or animals.

1-Dual GCGR/GLP-1R Receptor Pharmacology Research

Survo is used to examine GCGR and GLP-1R co-activation in receptor assay systems. Research endpoints include cAMP reporter assays, receptor competition binding, Gs-protein coupling, and pathway activation ratios.

2-Hepatic Cell Signalling Assays

Hepatic cell-based assays can examine GCGR-associated lipid signalling. Research endpoints include lipid accumulation staining, triglyceride quantification, and expression of lipid metabolism markers such as SREBP-1c, FAS, and ACC.

3- Energy Expenditure Pathway Research

Cell-based metabolic signalling studies can assess oxygen utilization, mitochondrial activity, and expression of pathway markers. These laboratory endpoints describe assay measurements rather than health outcomes.

4 – GLP-1 and Glucagon Receptor Signalling Interaction Studies

The molecular basis of synergistic vs additive vs antagonistic crosstalk between GLP-1R and GCGR intracellular pathways remains an active research area. Survo provides a single molecule that activates both receptor systems simultaneously, enabling research into shared second-messenger pathways (cAMP, PKA, CREB), cross-receptor phosphorylation events, and receptor internalisation/recycling dynamics under dual stimulation. Research endpoints: phospho-protein arrays for PKA substrates; CREB phosphorylation and transcriptional reporter assays; receptor internalisation kinetics (confocal imaging); beta-arrestin recruitment assays.

5 – Peptide Lipidation Chemistry and Albumin Binding Research

Survo’s C18 fatty diacid conjugation strategy represents one pharmacokinetic engineering approach among several being explored across the GLP-1/glucagon peptide class. Its C18 chain and glycine-serine hydrophilic spacer differ from GLP-1-Sm’s C18 conjugation at Lys26 and from AMY-Cg’s C20 chain ; providing a comparator for structure-PK relationship studies in lipidated peptide research. Research endpoints: albumin binding affinity and displacement kinetics (isothermal calorimetry / ITC; SPR); half-life characterisation in relevant research systems; comparative lipid chain hydrolysis stability studies; HPLC/LC-MS characterisation of acyl chain integrity.

6 – Analytical Chemistry and COA Verification Research

Survo’s molecular complexity (C₁₉₂H₂₈₉N₄₇O₆₁; ~4,232 Da; Ac4c non-coded residue; C18 acyl chain) requires multi-method analytical characterisation. Standard RP-HPLC purity cannot distinguish the intact lipidated compound from de-acylated impurities or sequence variants. Research endpoints: RP-HPLC purity profiling (C18 column, gradient elution); LC-MS full sequence and acyl chain verification; pH-dependent stability studies (aqueous buffer systems); ThT aggregation assay vs native glucagon; intact mass confirmation by high-resolution MS.

Structural & Chemistry Details

PubChem Structure Image (Public Domain ; NIH/NLM): https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?cid=168429725&t=l
Full Compound Page: https://pubchem.ncbi.nlm.nih.gov/compound/168429725
Alt Text for Structure Image: Survo (BI 456906; CID 168429725) full molecular structure ; C192H289N47O61 ; 29-residue dual GCGR/GLP-1R agonist showing glucagon-based peptide backbone, non-coded Ac4c residue at position 2, and C18 fatty diacid conjugation at position 24 via glycine-serine hydrophilic linker. Source: PubChem CID 168429725, NIH/NLM. For scientific research reference only. Not for human use.

Comparative Research Context ; 2026 GCGR/GLP-1R Peptide Landscape

The following table compares receptor profiles and molecular properties for laboratory reference.

Why Source Matters ; 3 Critical Quality Criteria

1-Acyl Chain Integrity Verification ; Not Just HPLC Purity

Standard RP-HPLC purity confirms bulk peptide content but cannot distinguish intact Survo (with its C18 fatty diacid conjugation) from the de-acylated apo-peptide. The acyl chain is the pharmacokinetic engineering element that confers albumin binding and extended half-life ; a structural feature relevant to albumin-binding assays. A research compound that has undergone hydrolysis of the acyl linkage will have fundamentally different pharmacology, PK properties, and receptor-binding kinetics. COA must include LC-MS molecular weight confirmation (~4,232 Da, intact) as a non-negotiable analytical requirement.

2-Ac4c Residue Verification and Sequence Confirmation
The Ac4c non-coded amino acid at position 2 is a critical receptor selectivity determinant. Peptide synthesis errors or substitution of this residue with a standard amino acid would produce a structurally similar but pharmacologically distinct compound. LC-MS sequence confirmation or tandem MS/MS fragmentation analysis capable of distinguishing Ac4c from adjacent residues is required for research-grade supply. Without this, researchers cannot confirm that what they are studying is pharmacologically equivalent to the Survo described in Zimmermann et al.

3-Cold-Chain Integrity and Endotoxin Documentation
Acylated peptide research compounds are sensitive to thermal degradation (acyl chain hydrolysis) and oxidative degradation at both the Ac4c residue and the C18 fatty diacid linkage. Lyophilised storage at −20°C or below under desiccated, hermetically sealed, light-protected conditions is required. Batch COA must include endotoxin data (<1.0 EU/mg by LAL assay) for relevant laboratory assays. Cold-chain documentation from manufacture through delivery is a marker of supply chain credibility. Suppliers without verifiable cold-chain controls should be considered unsuitable for research-grade Survo supply.

RESEARCH USE AND LABORATORY SAFETY

For laboratory research use only. Not for use in humans or animals. Not intended to treat, cure, or prevent any disease.

Use appropriate laboratory PPE and consult the SDS for handling information. Refer to batch COA documentation for identity, purity, lot traceability, and storage requirements.

Frequently Asked Questions

Q1: What is the intended research use of Survo?

Survo (BI 456906) is supplied as a Research Use Only (RUO) laboratory reagent for GCGR and GLP-1R assay studies. Not for use in humans or animals.

Q2: How is Survo classified?

Survo is supplied solely for controlled laboratory research. Not for use in humans or animals. Not intended to treat, cure, or prevent any disease.

Q3: What analytical data should be reviewed in the batch COA?

Review RP-HPLC purity, LC-MS identity and intact mass, lot number, storage information, and any reported endotoxin results. Sequence and lipidation characterization are relevant to this modified peptide.

Q4: What receptor profile is studied with Survo?

Survo is a dual GCGR and GLP-1R agonist research peptide. Receptor binding and signalling can be examined using defined laboratory assay systems.

Q5: What solvent information is relevant to Survo assay preparation?

Assess aqueous buffer compatibility, pH, solubility, and stability for the intended assay. Consult lot-specific handling documentation and prepare laboratory aliquots as appropriate for the analytical system.

Q6: What laboratory endpoints can be studied with Survo?

Examples include receptor binding, cAMP signalling, albumin binding, peptide aggregation, and acyl chain integrity. These are laboratory assay endpoints.

Q7: What is the Ac4c modification?

1-Aminocyclobutane-1-carboxylic acid (Ac4c) is a non-coded amino acid at position 2 of the peptide backbone. This structural feature is relevant to receptor selectivity and proteolytic stability studies.

Q8: What laboratory safety information applies to Survo?

Consult the SDS and applicable laboratory safety procedures. Use appropriate PPE during materials handling. Not for use in humans or animals.

Q9: What identification information accompanies Survo?

The catalog identifies Survo as BI 456906, CAS 2805997-46-8, and PubChem CID 168429725. Confirm the identity of the supplied lot against its COA.

Q10: Can Survo be used outside a laboratory research setting?

No. Survo is supplied for laboratory research only. Not for use in humans or animals.

Chemical Reference

PubChem (NIH/NLM), CID 168429725: molecular identity and structural reference.

RESEARCH USE ONLY ; NOT FOR HUMAN USE ; NOT FOR ANIMAL USE
All content for scientific education and controlled laboratory reference only | No medical claims made or implied | Compiled through March 2026